The following is a summary of the Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Inovio Pharmaceuticals reported a decrease in operational spend from $44.1M in Q1 2023 to $31.5M in Q1 2024, a decrease of 29%.

• The net loss for Q1 2024 is $30.5M ($1.31 loss per share), lower than the $40.6M loss ($1.89 loss per share) during the same period in 2023.

• The company concluded Q1 2024 with $105.6M in cash, cash equivalents, and short-term investments.

• Recently, the company raised approximately $33M through an offering of common stock and pre-funded warrants in April.

Business Progress:

• The company confirms its plan to file its BLA for 3107 in the second half of this year.

• In preparation for potential approval and commercialization of INO-3107, targeting recurrent respiratory papillomatosis.

• The FDA has given approval for the company to proceed with the Phase 3 trial for INO-3112 in combination with LOQTORZI for throat cancer.

• Plans for a Phase 2/3 study with INO-4201 as an Ebola vaccine booster are expected to be submitted in the current quarter.

• Inovio Pharmaceuticals is continuing its advancement on the Phase 3 trial for INO-3112, and is also expanding its commercial activities post-fundraising.

More details: Inovio Pharmaceuticals IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.